The Essence of Cell Therapy for the Heart Presented to Top Thai Cardiologists
Top Thai cardiologists gather for the first time for a symposium in cell therapy
Bangkok, Thailand, October 27th, 2004 – The science of cell therapy and details about the ongoing clinical trial using endothelial progenitor cells for severe ischemic heart disease were presented to the top Thai cardiologists for the first time. The event, hosted by Theravitae Co., Ltd., the company sponsoring the clinical trial at the Siriraj Hospital, in Bangkok was held exclusively for Thai cardiologists.
Associate Professor Damras Tresukosol, MD, Head of the Invasive Unit, Director of the Catheterization Laboratory of Her Majesty’s Cardiac Center, Faculty of Medicine, Siriraj Hospital and principal investigator of the study, had presented the current status of the clinical trial which is actively recruiting patients with severe angina pectoris to be treated by using cell therapy technology. “With this cutting-edge medical technology we might be able to give hope to the once hopeless patients, and we would like to share this knowledge with our fellow cardiologists.” said Professor Damras. Dr. Valentin Fulga, Chief Executive Officer of Theravitae presented the background science as well as a brief description of the company. An open discussion took place after the presentations sparking ideas and possibilities that in the near future the Thai medical society may benefit from cell therapy.
Professor Suphachai Chaithiraphan, MD, President of the Heart Association of Thailand and President of the Thai Atherosclerosis Society, chaired the symposium.
The cell therapy clinical trial, sponsored by Theravitae, is now enrolling patients with recurring chest pain on maximal medical therapy which are eligible according to certain inclusion or exclusion criteria (http://www.theravitae.com/eligibility.php). Eligible patients should be referred to the cardiology department at Siriraj Hospital or Theravitae.
TheraVitae is an emerging biotechnology company with the prime mission to offer novel, cutting edge cell therapies to patients worldwide. Initially, the Company focuses on the treatment of cardiovascular disorders. Other cell-based treatments for severe disorders, such as glaucoma and age-related macular degeneration, are under development.
For additional information contact Dr. Veerachat Petpisit, Marketing Director, Theravitae Co., Ltd. +66(2)6644290, email@example.com, www.theravitae.com
For more information:Editor's DetailsNattapot
TheraVitae Co., Ltd.http://www.theravitae.com
+(66) 2 664 firstname.lastname@example.org
Last updated on: 27/08/2010